NEW YORK (GenomeWeb) – OpGen will meet with a Nasdaq panel in early 2018 to stave off being delisted from the exchange, the company said in a regulatory document on Tuesday.

In a Form 8-K filing with the US Securities and Exchange Commission, OpGen said that it received written notice on Dec. 21 from Nasdaq informing the company that the exchange would be delisting its stock on Jan. 2, 2018 if it did not request a hearing with a Nasdaq Hearing Panel in relation to the firm's failure to meet certain listing requirements.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.